MMWR Morb Mortal Wkly Rep. 2006 Feb 10;55(5):127.
On February 3, 2006, the Food and Drug Administration (FDA) announced clearance of the Influenza A/H5 (Asian Lineage) Virus Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Primer and Probe Set and inactivated virus as a source of positive RNA control for the in vitro qualitative detection of highly pathogenic influenza A/H5 virus (Asian lineage). Two genetic lineages of influenza A/H5 viruses exist: Eurasian (Asian) and North American. The primer and probe set, developed at CDC, is designed to detect highly pathogenic influenza A/H5 viruses from the Asian lineage associated with recent laboratory-confirmed infections of avian influenza in humans in east Asia and, most recently, in Turkey and Iraq.
2006年2月3日，美国食品药品监督管理局（FDA）宣布批准甲型/ H5（亚洲株系）流感病毒实时逆转录-聚合酶链反应（RT-PCR）引物和探针组以及灭活病毒，作为体外定性检测高致病性甲型/ H5病毒（亚洲株系）的阳性RNA对照来源。甲型/ H5流感病毒有两个基因株系：欧亚（亚洲）株系和北美株系。该引物和探针组由美国疾病控制与预防中心（CDC）研发，旨在检测与东亚地区近期经实验室确诊的人类禽流感感染病例相关的亚洲株系高致病性甲型/ H5流感病毒，以及最近在土耳其和伊拉克出现的相关病毒。
